Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1554 Trials   75234 News 


«12...6061626364656667686970...858859»
  • ||||||||||  astegolimab (RG 6149) / Amgen, Roche
    Journal:  Mechanistic role of RND3-regulated IL33/ST2 signaling on cardiomyocyte senescence. (Pubmed Central) -  May 21, 2024   
    NF-?B inhibitor pyrrolidinedithiocarbamate ammonium (PDTC) and ST2 antibody astegolimab treatments mitigated above effects...In contrast, RND3 overexpression in rats by injection of AAV9-CMV-RND3 particles inhibited IL33, ST2L, IL1?, IL6, and MCP1 expression in cardiac tissues, decreased serum IL33 levels, and increased sST2 levels. These results suggest that RND3 expression in cardiomyocytes modulates cell senescence by inhibiting the IL33/ST2/NF-?B signaling pathway, underscoring its potential as a therapeutic target in cardiovascular senescence.
  • ||||||||||  Krazati (adagrasib) / BMS, Lumakras (sotorasib) / Amgen
    Review, Journal:  Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer. (Pubmed Central) -  May 21, 2024   
    In the coming years, there will likely be advancements in the development of more efficacious pharmaceuticals and targeted therapeutic approaches for treating NSCLC and CRC. Consequently, individuals with KRAS-mutant NSCLC may experience a prolonged response duration and improved treatment outcomes.
  • ||||||||||  Vectibix (panitumumab) / Amgen
    Journal:  Intravitreal panitumumab and myopic macular degeneration. (Pubmed Central) -  May 21, 2024   
    In this open-labelled, phase-1 study with a mean follow-up of 6.7 months, panitumumab repeatedly administered intravitreally up to a dose of 1.8?mg was not associated with intraocular or systemic adverse effects. During the study period, axial length remained unchanged.
  • ||||||||||  Review, Journal, Head-to-Head:  Head-to-head studies on radiographic progression in axial spondyloarthritis (Pubmed Central) -  May 21, 2024   
    Therefore, for the endpoint of radiological progression no difference could be shown in the inhibition of radiological progression between the mechanisms of action investigated. The comparative data for the endpoint of clinical efficacy showed that patients with bDMARDs showed a clearly better response to treatment than patients with NSAR or conventional synthetic DMARDs (csDMARD).
  • ||||||||||  efruxifermin (AKR-001) / Akero Therap
    Insulin-Sensitizing Effects of Efruxifermin Improve Glycemic Control in Patients with MASH and Type 2 Diabetes (Poster Hall (West A4-B2); 897) -  May 20, 2024 - Abstract #ADA2024ADA_2904;    
    EFX has consistently improved markers of whole-body glucose and lipid metabolism in patients with MASH and T2D, even on top of stable T2D medications including GLP-1RA. EFX-mediated insulin sensitization may potentiate effects of insulin or insulin secretagogues, possibly enabling patients to reduce use of insulin and/or other T2D medications to mitigate weight gain, incidence of hypoglycemia, or other side effects.
  • ||||||||||  Mounjaro (tirzepatide) / Eli Lilly, efruxifermin (AKR-001) / Akero Therap
    Tirzepatide and Efruxifermin Demonstrate Therapeutic Benefits for NASH in a Preclinical Metabolic Syndrome Animal Model, B6-Alms1-del Mice (Poster Hall (West A4-B2); 1639) -  May 20, 2024 - Abstract #ADA2024ADA_2586;    
    Consistently, Efruxifermin treatment exhibited more significant NASH resolution than Tirzepatide treatment.In summary, we demonstrated the therapeutic effects of Tirzepatide and Efruxifermin in B6-Alms1-del mice, which aligned with recent clinical observations. Consequently, B6-Alms1-del mice could serve as a valuable model for preclinical studies of anti-NASH agents targeting GLP-1R/GIPR and FGF21.
  • ||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen
    Trial completion date, Trial termination, Trial primary completion date, Gene therapy:  FANCA: Gene Therapy for Fanconi Anemia (clinicaltrials.gov) -  May 20, 2024   
    P1,  N=3, Terminated, 
    No abstract available Trial completion date: Jul 2032 --> Feb 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2032 --> Feb 2024; Study ended early due to end of funding.
  • ||||||||||  omecamtiv mecarbil (AMG 423) / Amgen, Servier
    Review, Journal:  Challenging and target-based shifting strategies for heart failure treatment: An update from the last decades. (Pubmed Central) -  May 19, 2024   
    Moreover, soluble guanylate cyclase stimulator, elamipretide, and omecamtiv mecarbil have come out as a next-generation therapeutic agent for patients with HF...Such tempting therapies still have some challenges to be addressed but may become a weighty option for treatment of HF. This review article will compile the paradigm shifts in HF treatment over the past dozen years or so and illustrate current landscape of antibody-based immunotherapy and gene therapy as a new therapeutic algorithm for patients with HF.
  • ||||||||||  tapotoclax (AMG 176) / Amgen
    Journal:  A multitier virtual screening study of phytoconstituents as Myeloid Cell Leukemias 1 inhibitors. (Pubmed Central) -  May 19, 2024   
    One phytoconstituent, Isopongaflavone, was identified that exhibiting higher docking and drug-likeness than the already reported MCL1 inhibitor, Tapotoclax...This investigation proposes Isopongaflavone as a promising candidate for the development of innovative anticancer therapeutics, pending the necessary validation procedures. Also, the findings provide valuable information for designing MCL1 inhibitors based on the protein's structure.Communicated by Ramaswamy H. Sarma.
  • ||||||||||  Doptelet (avatrombopag) / SOBI
    Immune Thrombocytopenia treated with Avatrombopag in a Kidney Transplant Recipient (Exhibition Hall) -  May 17, 2024 - Abstract #ISTH2024ISTH_1326;    
    This was on a background of renal transplantation for which he remained significantly immunosuppressed with prednisone and tacrolimus. The sudden onset thrombocytopenia initially occurred in the setting of a severe COVID-19 infection with a superimposed bacterial/fungal pneumonia and CMV viraemia.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Nplate (romiplostim) / Amgen, Kyowa Kirin, Rituxan (rituximab) / Roche
    Pharmacovigilance study of Drug associated Evans syndrome: Analysis of FAERS database (Exhibition Hall) -  May 17, 2024 - Abstract #ISTH2024ISTH_1298;    
    The distribution was 46.2% in males and 39.7% in females. 18.2% patients were below 18 years of age, 57.9% were adults, and 23.8% patients had age not defined.
  • ||||||||||  Nplate (romiplostim) / Amgen, Kyowa Kirin, Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis
    Management of Chronic ITP with TPO-mimetics- Single Centre Experience at Birmingham Children (Exhibition Hall) -  May 17, 2024 - Abstract #ISTH2024ISTH_1289;    
    In the eltrombopag cohort (23 females, 17 males), 2 children exhibited no response. Among the 38 responders, 9 experienced a loss of response, while 6 successfully discontinued eltrombopag and maintained stable platelet counts.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche
    Retrospective data, Journal, Monotherapy, Metastases:  Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study. (Pubmed Central) -  May 17, 2024   
    Previous therapy with fruquintinib or regorafenib was allowed but not mandatory...Multivariate Cox regression analysis demonstrated that undergoing therapy after TAS-102 either with or without BEV was an independent risk factor for OS [hazard ratio (HR) =0.25; 95% confidence interval (CI): 0.09-0.71, P<0.01], and previous treatment with cetuximab was an independent protective factor for PFS (HR =0.17; 95% CI: 0.03-0.91, P=0.04)...There was a trend in favor of the combination of BEV plus TAS-102 regarding OS and DCR, without reaching statistical significance, and it means that there was no clear advantage of one over the other in terms of efficacy. Further prospective studies are still necessary to draw a definite conclusion.
  • ||||||||||  Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Tomudex (raltitrexed) / Pfizer, AstraZeneca
    Retrospective data, Journal, Metastases:  Efficacy and safety of gemcitabine plus raltitrexed or S-1 versus standard third-line therapies in metastatic colorectal cancer: a retrospective cohort study. (Pubmed Central) -  May 17, 2024   
    After the failure of standard first- and second-line treatments, including oxaliplatin, irinotecan, and 5-fluorouracil (5-FU) combined with targeted drugs, the currently recommended third-line regimens for metastatic colorectal cancer (mCRC) include TAS-102, regorafenib, and fruquintinib...Patients with previous failures of at least two lines of standard therapy with oxaliplatin, 5-FU, irinotecan, or capecitabine combined with targeted drugs were included...A typical case is presented in this article. The gemcitabine plus raltitrexed or S-1 regimen is a potential regimen with tolerable adverse reactions and low cost for patients with mCRC.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Journal, Surgery:  Outcomes of Strabismus Surgery Following Teprotumumab Therapy. (Pubmed Central) -  May 16, 2024   
    We recommend future well-designed studies to further evaluate the use of neoadjuvant denosumab for patients with spinal GCT. Most patients requiring surgery for strabismic diplopia following teprotumumab achieve good outcomes with success rates comparable to series published before the availability of teprotumumab.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal, HEOR:  Comparative effectiveness of Denosumab vs alendronate among postmenopausal women with osteoporosis. (Pubmed Central) -  May 16, 2024   
    In this cohort of almost half-a-million treatment-naive women with PMO, we observed clinically significant reductions in the risk of MOP, hip, NV, NHNV, and HV fractures for patients on denosumab compared with alendronate. Patients who remained on denosumab for longer periods of time experienced greater reductions in fracture risk.
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Journal:  The use of anabolic agents in the treatment of osteoporosis: a clinical update. (Pubmed Central) -  May 16, 2024   
    Voxelotor resulted in a clinically significant difference in the percent change of hemoglobin from baseline to 3?months. Integrating anabolic agents into personalized treatment plans has the potential to significantly improve outcomes and quality of life for patients with severe osteoporosis, highlighting the importance of this therapeutic class in the management of this chronic condition.